Halozyme Therapeutics, Inc. (HALO) PT Raised to $20.00
Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price objective raised by equities research analysts at Deutsche Bank AG to $20.00 in a report issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price would suggest a potential upside of 23.08% from the company’s current price.
Other equities research analysts also recently issued research reports about the company. BidaskClub downgraded Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Friday, August 11th. Canaccord Genuity set a $16.00 price objective on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. Jefferies Group LLC reaffirmed an “underperform” rating and issued a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Finally, ValuEngine raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $16.00.
Halozyme Therapeutics (HALO) opened at 16.25 on Friday. The stock’s 50 day moving average price is $12.79 and its 200-day moving average price is $13.23. The stock’s market capitalization is $2.18 billion. Halozyme Therapeutics has a 12-month low of $8.18 and a 12-month high of $16.65.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. Halozyme Therapeutics’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.21) EPS. Analysts expect that Halozyme Therapeutics will post ($0.88) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $171,000. Verition Fund Management LLC grew its position in Halozyme Therapeutics by 50.4% during the second quarter. Verition Fund Management LLC now owns 20,499 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 6,866 shares during the period. The Manufacturers Life Insurance Company grew its position in Halozyme Therapeutics by 524.7% during the second quarter. The Manufacturers Life Insurance Company now owns 1,011,449 shares of the biopharmaceutical company’s stock valued at $12,968,000 after acquiring an additional 849,545 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $131,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $541,000. 85.08% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.